---
created: 2025-04-13
updated: 2025-04-13T10:52
id: Otl?ho8wR~
specialty: endo
specialty_id: 69
tags:
  - source/ak-original-decks::step-1::zanki-pharmacology
  - "source/ak-step1-v11:": 
  - theme/b&b::08-endocrinology::03-pancreas::04-treatment-of-diabetes
  - "source/ak-step1-v11:": 
  - theme/firstaid::08-endocrine::05-pharm::01-diabetes-mellitus-therapy
  - "source/ak-step1-v11:": 
  - theme/firstaid::08-endocrine::05-pharm::01-diabetes-mellitus-therapy::sglt2-inhibitors
  - "source/ak-step1-v11:": 
  - theme/ome::14-endocrine::05-pancreas::03-diabetes-pharm
  - "source/ak-step1-v11:": 
  - source/ome-banner::clinical::07-endocrinology::06-outpatient-diabetes
  - "source/ak-step1-v11:": 
  - theme/physeo::09-pharm::07-endocrine::07-sodium-glucose-cotransporter-2-(sglt2)-inhibitors
  - "source/ak-step1-v11:": 
  - theme/sketchypharm::05-gi-&-endocrine::02-diabetes::02-metformin,-thiazolidinediones,-pramlintide,-sglt2-inhibitors
  - "source/ak-step1-v11:": 
  - theme/uworld::10000-99999::18000-18999::18956
  - "source/ak-step1-v11:": 
  - theme/uworld::10000-99999::18000-18999::18959
  - source/ak-step1-v11::^other::^highyield::1-highyield
  - source/ak-step1-v11::^systems::endocrine::pharmacology
  - source/ak-step2-v11::!shelf::fm
  - source/ak-step2-v11::!shelf::fm::no-dupes
  - source/ak-step2-v11::!shelf::im
  - source/ak-step2-v11::!shelf::im::no-dupes
  - "source/ak-step2-v11:": 
  - theme/ome::07-endocrinology::05-outpatient-diabetes
  - "source/ak-step2-v11:": 
  - source/ome-banner
  - "source/ak-step2-v11:": 
  - theme/resources-by-rotation::fm::ome::endo::outpatient-dm
  - "source/ak-step2-v11:": 
  - theme/resources-by-rotation::im::ome::endo::outpatient-dm
  - "source/ak-step2-v11:": 
  - theme/subjects::endocrinology::06-pancreas::diabetes::*management-redo
  - source/ak-step2-v11::original-decks::dorian::fam::ome::endo::outpatient-dm
  - source/ak-step2-v11::original-decks::dorian::im::ome::endo::outpatient-dm"
type: flashcard
---

# Question
Canagliflozin, dapagliflozin, and empagliflozin are all examples of **SGLT2** inhibitors

---

# Answer
Sodium-glucose cotransporter-2 (SGLT-2) inhibitor  ~ increased urine glucose concentration == UTIs (eg, pyelonephritis), genital mycotic infections (eg, vaginitis), and necrotizing fasciitis of the perineum (ie, Fournier gangrene)